Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 55

1.

Surveillance for antiviral resistance.

Zambon MC.

Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1:37-43. doi: 10.1111/irv.12050.

2.

Evaluation of influenza virus antiviral susceptibility testing in Europe: results from the first external quality assessment exercise.

Thompson CI, Lackenby A, Daniels RS, McCauley JW, Pereyaslov D, Broberg EK, Meijer A, Zambon MC.

J Clin Virol. 2013 Mar;56(3):212-8. doi: 10.1016/j.jcv.2012.11.005. Epub 2012 Nov 30.

PMID:
23201459
3.

Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard.

Wood JM, Major D, Heath A, Newman RW, Höschler K, Stephenson I, Clark T, Katz JM, Zambon MC.

Vaccine. 2012 Jan 5;30(2):210-7. doi: 10.1016/j.vaccine.2011.11.019. Epub 2011 Nov 17.

PMID:
22100887
4.

Fatal cases of influenza a in childhood.

Johnson BF, Wilson LE, Ellis J, Elliot AJ, Barclay WS, Pebody RG, McMenamin J, Fleming DM, Zambon MC.

PLoS One. 2009 Oct 30;4(10):e7671. doi: 10.1371/journal.pone.0007671.

5.

Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.

Nicholson KG, Thompson CI, Klap JM, Wood JM, Batham S, Newman RW, Mischler R, Zambon MC, Stephenson I.

Vaccine. 2009 Dec 10;28(1):171-8. doi: 10.1016/j.vaccine.2009.09.103. Epub 2009 Sep 30.

PMID:
19799843
6.

Reproducibility of serologic assays for influenza virus A (H5N1).

Stephenson I, Heath A, Major D, Newman RW, Hoschler K, Junzi W, Katz JM, Weir JP, Zambon MC, Wood JM.

Emerg Infect Dis. 2009 Aug;15(8):1252-9. doi: 10.3201/eid1508.081754.

7.

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

Stephenson I, Nicholson KG, Hoschler K, Zambon MC, Hancock K, DeVos J, Katz JM, Praus M, Banzhoff A.

N Engl J Med. 2008 Oct 9;359(15):1631-3. doi: 10.1056/NEJMc0805274. No abstract available.

8.

Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies.

Lackenby A, Democratis J, Siqueira MM, Zambon MC.

Antivir Ther. 2008;13(6):809-20.

PMID:
18839782
9.

Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.

Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.

Vaccine. 2008 Nov 25;26(50):6383-91. doi: 10.1016/j.vaccine.2008.08.046. Epub 2008 Sep 16.

PMID:
18801398
10.

Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.

Nolan TM, Richmond PC, Skeljo MV, Pearce G, Hartel G, Formica NT, Höschler K, Bennet J, Ryan D, Papanaoum K, Basser RL, Zambon MC.

Vaccine. 2008 Aug 5;26(33):4160-7. doi: 10.1016/j.vaccine.2008.05.077. Epub 2008 Jun 13.

PMID:
18599164
11.

Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe.

Lackenby A, Hungnes O, Dudman SG, Meijer A, Paget WJ, Hay AJ, Zambon MC.

Euro Surveill. 2008 Jan 31;13(5). pii: 8026. No abstract available.

12.

Establishment of a UK National Influenza H5 Laboratory Network.

Curran MD, Ellis JS, Wreghitt TG, Zambon MC.

J Med Microbiol. 2007 Oct;56(Pt 10):1263-7. Review.

PMID:
17893159
13.

Cross-neutralisation of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains.

Höschler K, Gopal R, Andrews N, Saville M, Pepin S, Wood J, Zambon MC.

Influenza Other Respir Viruses. 2007 Sep-Nov;1(5-6):199-206. doi: 10.1111/j.1750-2659.2007.00033.x.

14.

Generation of candidate human influenza vaccine strains in cell culture - rehearsing the European response to an H7N1 pandemic threat.

Whiteley A, Major D, Legastelois I, Campitelli L, Donatelli I, Thompson CI, Zambon MC, Wood JM, Barclay WS.

Influenza Other Respir Viruses. 2007 Jul;1(4):157-66. doi: 10.1111/j.1750-2659.2007.00022.x.

15.
16.

Infection of human airway epithelium by human and avian strains of influenza a virus.

Thompson CI, Barclay WS, Zambon MC, Pickles RJ.

J Virol. 2006 Aug;80(16):8060-8.

17.

Modelling hospital admissions for lower respiratory tract infections in the elderly in England.

Müller-Pebody B, Crowcroft NS, Zambon MC, Edmunds WJ.

Epidemiol Infect. 2006 Dec;134(6):1150-7. Epub 2006 May 26. Review.

18.

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC.

Lancet. 2006 May 20;367(9523):1657-64.

PMID:
16714186
19.

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.

Stephenson I, Zambon MC, Rudin A, Colegate A, Podda A, Bugarini R, Del Giudice G, Minutello A, Bonnington S, Holmgren J, Mills KH, Nicholson KG.

J Virol. 2006 May;80(10):4962-70.

20.

Rates of hospitalisation for influenza, respiratory syncytial virus and human metapneumovirus among infants and young children.

Nicholson KG, McNally T, Silverman M, Simons P, Stockton JD, Zambon MC.

Vaccine. 2006 Jan 9;24(1):102-8. Epub 2005 Feb 25.

PMID:
16310899
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk